Hamsa Thayele Purayil, Ph.D.
Office: BSU B1-003G
Phone: (352) 273-8244
Education & Training
Ph.D. – Mahathma Gandhi University, Kerala, India (2011)
M.S. Biotechnology – Cochin University of Science and Technology, India (2002)
B.S. Zoology – Kannur University, India (1999)
Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells, if the spread is not controlled, it can result in death. In spite of major advancements in the field of medicine and technology, cancer still continues to be a threat to public health in the United States and other parts of the world. Prostate cancer, one of the most commonly diagnosed malignancies and the second leading cause of cancer-related deaths in American men. Patients with advanced prostate cancer are generally treated with hormonal therapies that block the function of the androgen receptor. Although these therapies are initially effective, the mortality rate increases owing to the recurrence of castration-resistant prostate cancer. Our research mainly focuses on the understanding of the CRPC progression and molecular pathways or proteins that are involved in the regulation of this transformation to castration resistant phenotype. We found that βarrestin1 regulates the androgen receptor activity under castration resistant condition which results in tumor progression and metastasis.
Xiaojie Ma, Laura Espana-Serrano, Wan-ju Kim, Hamsa Thayele Purayil, Zhongzhen Nie, Yehia Daaka. (2014): β Arrestin-1 regulates RasGRF2 expression and Rac-mediated formation of membrane protrusion and cell motility. J Biol Chem; (19):13638-50. | PubMed
Hamsa TP, Kuttan G. (2011). Ipobscurine, an indole alkaloid from Ipomoea obscura, inhibits tumor cell invasion and experimental metastasis by inducing apoptosis. J Env Pathol Toxicol Oncol; 30(2): 163-178. | PubMed
Hamsa TP, Kuttan G. (2011). Inhibition of invasion and experimental metastasis of murine melanoma cells by Ipomoea obscura (L.) is mediated through the down-regulation of inflammatory mediators and matrix-metalloproteinases. J Exp Ther Oncol; 9(2): 139-51. | PubMed